Participated · Series B · Oct 2025

Ansa Biotechnologies is a DNA synthesis company based in Emeryville, CA that focuses on producing sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments. Its platform aims to give scientists rapid, accurate access to synthetic DNA for applications across healthcare, life sciences, and other industries. To reinforce reliability, the company recently launched the Ansa On-Time Guarantee, promising that any order not shipped in full and on time will be provided free of charge. It has also rolled out a new pricing framework targeting low-complexity DNA sequences to make routine orders more cost-effective. With its latest capital infusion, Ansa plans to expand U.S. manufacturing capacity, deepen customer-experience initiatives, and strengthen strategic partnerships while advancing its technology stack. Although no revenue or user figures were disclosed, the firm’s continued fundraising indicates growing market traction and operational scaling needs.

Participated · Series A · Sep 2025

Lila Sciences develops an AI-driven platform that trains models on scientific literature across material sciences, chemistry and life sciences and generates experimental hypotheses. The company pairs those model outputs with laboratory setups to experimentally validate and close the loop between prediction and reproducible results. Reporting says Lila aims for a domain‑crossing, general-purpose science enablement stack rather than narrowly focused tools. Financially, it has completed a reported $200 million seed, emerged from stealth last year, and closed a $350 million Series A in October that lifted its valuation above $1.3 billion. Current reporting describes Lila negotiating an approximately $2 billion financing to scale compute, inference and laboratory capacity and to accelerate partner programs. The firm's growth narrative emphasizes standardizing experiment and feedback loops to make discovery repeatable and scalable.

Participated · Series A · Jun 2024

Vilya builds a proprietary computational drug design and development platform that uses advanced machine learning and generative AI to design de novo molecular structures. The company focuses on novel macrocycles—molecules sized between small molecules and antibodies—to target previously difficult-to-drug therapeutic targets. It is advancing a pipeline of these macrocycles intended to precisely target disease biology. Vilya intends to use new funding to accelerate both its platform development and its therapeutic pipeline. The company’s scientific leadership includes David Baker, Ph.D., and its executive team includes CEO Cyrus Harmon, Ph.D., Chief Scientific Officer Katerina Leftheris, Ph.D., Co‑Founder and CTO Patrick Salveson, Ph.D., and Co‑Founder and VP Business Development Inca Dieterich, Ph.D. Vilya has operations in Seattle and South San Francisco. Vilya operates a proprietary platform powered by advanced machine learning to design de novo molecular structures that sit between small molecules and antibodies. The company’s artificial, biologic‑like molecules are engineered to be membrane‑permeable, disrupt protein‑protein interactions, and be highly selective for their targets. IPD scientists published a Cell paper describing accurate de novo design of membrane‑traversing macrocycles that underpin Vilya’s foundational technology. Vilya intends to leverage this computational design capability to pursue previously difficult‑to‑drug therapeutic targets across a broad set of indications. The company launched in Seattle with $50 million in committed Series A financing led by ARCH Venture Partners. Its co‑founding team combines researchers from the Institute of Protein Design and leaders from ARCH Venture Partners.

Participated · Series A · Jun 2023

Mozart Therapeutics develops CD8 Treg modulators to create disease-modifying therapies for autoimmune and inflammatory diseases. Its lead candidate, MTX-101, is a bispecific autoimmune checkpoint inhibitor planned for IND submission and a Phase 1 first-in-human trial in early 2024. An additional cytokine-based CD8 Treg network modulator is in preclinical development. The company is led by President and CEO Katie Fanning. Mozart intends to use the new funding to advance MTX-101 into human trials and to support pipeline expansion. Financially, the company expanded its Series A with a $25M extension, bringing total capital raised to $80M. Mozart Therapeutics is a Seattle biotech developing compounds that boost regulatory CD8 T cells to quell overactive immune responses in celiac disease and other autoimmune and inflammatory conditions. Its lead compound aims to increase activity of regulatory CD8 T cells and move through preclinical studies into human testing, with celiac disease trials expected to start in 2024. The company is also building bispecific compounds that bind regulatory CD8 T cells and inhibit the KIR brake, and it has additional compounds targeting different surface receptors. Programs build on research from co-founder Mark Davis’s lab at Stanford, and Mozart believes the approach may apply to type 1 diabetes and inflammatory bowel disease as well. Leadership includes CEO Katie Fanning, CSO Kristine Swiderek, and VP Courtney Crane; the roughly 13-person company plans to expand hires in research and product development. Mozart operates out of lab space near Seattle’s waterfront and raised capital to advance its lead program toward human trials.

Led · Series C · Mar 2023

Ring Therapeutics is a Cambridge, MA life sciences company developing gene therapies and nucleic acid medicines by harnessing the human commensal virome, specifically anelloviruses. The company has developed the Anellogy platform, which generates diverse vectors with tissue-specific tropism and the potential to be re-dosed. Ring says the platform could be applied to a broad range of diseases. Founded by Flagship Pioneering in 2017, the company is led by CEO Tuyen Ong and Co-Founder and Chairman Avak Kahvejian. Ring raised an $86.5M Series C that brought total capital raised to date to $230M. The company intends to use the funds to expand operations and advance the Anellogy platform toward the clinic. Ring Therapeutics, founded by Flagship Labs in 2017 and based in Cambridge, Mass., develops anellovirus-based vector technologies under its Anellogy™ platform. The company has built a proprietary vector bioplatform to discover and vectorize commensal anelloviruses and produce programmable medicines called Anellovectors™. Anellovectors carry circular single-stranded DNA that is non-integrating, can be engineered for tissue-specific tropism, delivered through multiple routes, and potentially re-dosed without inducing adverse immune responses. The platform is positioned to support a broad spectrum of therapeutic modalities including gene therapies and nucleic acid medicines. Ring raised $117M in a Series B and intends to use the funds to continue development and expand the Anellogy platform. The company is led by CEO Dr. Tuyen Ong with Avak Kahvejian, Ph.D., serving as chairman.